Navigation Links
Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
Date:7/29/2010

al signals across a broad spectrum of exploratory efficacy measures is also encouraging, especially considering that these patients had clinically stable symptoms at study entry," stated Sharon Mates, Chief Executive Officer of Intra-Cellular Therapies.  "We believe that the favorable clinical profile is consistent with ITI-007's unique pharmacology."

SUMMARY OF ITI-007 PHASE IB/II STUDY RESULTS

The Phase Ib/II study was a randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability and pharmacokinetic profile of ITI-007 in patients with stable schizophrenia.  Exploratory endpoints included clinical assessments to evaluate the symptoms of schizophrenia (PANSS) and symptoms of depression (CDSS).  Forty-five patients were randomized to receive ITI-007 or placebo once daily for five days.  Oral doses of ITI-007 up to and including 140 mg were found to be safe and well-tolerated with repeated administration in patients with stable schizophrenia who had been withdrawn from their previous antipsychotic medications.  In an earlier Phase II sleep efficacy trial, low doses of 1-10 mg ITI-007 were shown to significantly improve sleep in patients with insomnia.  In the present study, patients with schizophrenia also anecdotally reported improvements in sleep.  Even at the highest doses of ITI-007 tested, all adverse events were mild to moderate.  Notably, there were no extrapyramidal side effects (EPS) and no cognitive impairment, side effects that are often observed following treatment with other antipsychotic drugs at high doses.  Total cholesterol and triglyceride levels decreased following withdrawal from previous antipsychotic drugs and while being treated with ITI-007.  Pharmacokinetic profiles suggest a once-a-day treatment regimen will be sufficient to achieve
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
2. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
3. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
5. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
6. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
7. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
8. Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity
9. Reportlinker Adds Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies
10. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
11. Drug in New Class of Targeted Therapies Shows Early Promise Against Blood-Related Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... PAUL, Minn. , May 23, 2013  MGC ... Corporation), a global medical technology company, today scheduled a ... second quarter of fiscal year 2013, ended April 30, ... on Thursday, May 30, 2013. The Company will report ... 2013 after the markets close on Thursday, May 30, ...
(Date:5/23/2013)... DIEGO , May 23, 2013  The ... prostate cancer treatment continuum was highlighted prominently at ... American Urological Association (AUA), in San Diego.  According ... high intensity focused ultrasound (HIFU) technology, the need ... disease, and for urologists to consider minimally invasive ...
(Date:5/23/2013)...  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing ... announced that it has initiated dosing in a Phase ... oral therapy for the treatment of HCV infection. This study ... designed to assess both the safety and antiviral efficacy ... for the treatment of chronic HCV infections and is ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
(Date:5/25/2013)... May 25, 2013 Communities of Distinction ... It is the fifth largest media market in the United ... number one visitor destination in Texas and a major convention ... the American West as it is home to many major ... enjoy from sports to the arts. Residents and locals will ...
(Date:5/25/2013)... -- Animals make great companions for senior citizens, but elderly ... are far more likely to crash than those who never ... study included 2,000 licensed drivers aged 70 and older. The ... they drove with their pet in the car. Among ... was twice as high as among those who never drove ...
(Date:5/25/2013)... Louis, MO (PRWEB) May 25, 2013 Providing ... for the Diet Doc team of weight management professionals. But, ... fast and effectively, Diet Doc’s hCG diets ... factors like abuse during childhood like bullying, more control over ... directly capable of dealing with the underlying factors of weight ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The ... ranging from irritable bowel syndrome (IBS) to bloating, ... among the most long-lasting, embarrassing, frustrating and difficult ... foods for digestive health have provided a ... are many factors contributing to digestive health issues, ...
(Date:5/25/2013)... orthodontists have thought about moving their office to the ... Most people would naturally assume that the company they'd ... and support would own and maintain all the physical ... wrong. Cloud providers lease space in a ... servers and related equipment to run cloud environments) owned ...
Breaking Medicine News(10 mins):Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2Health News:Seniors More Likely to Crash When Driving With Pet: Study 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Cirrus Ortho Launches Cloud Computing for Orthodontic Industry That is Unlike Any Other 2
... in Complex Rehab IndustryWILKES-BARRE, Pa., March 11 James ... years of experience, has joined Alliance Seating & ... accredited complex rehab companies. Conwell is an Assistive ... Supplier (CRTS) in Wilkes-Barre, Pa., for ASM ( www.alliance-seating.com ...
... Prevention, Treatment and Care Services for People around ... March 11 Late yesterday the ... Omnibus Appropriations bill for fiscal year 2009. ... last week, contains an appropriation of $900 million ...
... The U.S. Agency for International Development (USAID) ... launched a new program to reduce HIV vulnerability of ... The three-year, $5.1 million project is funded by the ... administered by USAID . A recent release study ...
... of cancer cells and their frequent divisions have their ... cells. Their metabolism runs at full speed and requires ... of iron in the cell lead to the production ... these, the cell inactivates free iron by binding it ...
... Amex: FHC ) today announced that it will ... of the FC2 Female Condom(R) on Thursday, March ... Company announced its receipt of FDA approval for the ... Shareholders and other interested parties may participate in the conference ...
... ROSEMONT, Ill., March 11 /PRNewswire-USNewswire/ -- Orthopaedic surgeon ... of Councilors (BOC) of the American Academy of ... the Venetian Sands Expo Center in Las Vegas. He ... "As Secretary, I will be one of the voices for ...
Cached Medicine News:Health News:Veteran Rehab Specialist, James Conwell, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania 2Health News:Congress Approves FY2009 Omnibus Appropriations Bill with $900 Million for The Global Fund 2Health News:USAID and IOM Announce HIV Prevention and Care for Farm Workers 2Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 2Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 3Health News:David Teuscher, MD, Elected Secretary of Academy Board of Councilors 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: